The FDA has approved bexarotene (Targretin; Ligand Pharmaceuticals Inc, San Diego) for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who have not responded to at least one prior systemic treatment. Bexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors, which when activated function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene, a member of a class of retinoids associated with birth defects in humans, must not be given to a pregnant woman who is, or intends to become, pregnant.
Henney JE. New Drug for Refractory Cutaneous T-Cell Lymphoma. JAMA. 2000;283(9):1131. doi:10.1001/jama.283.9.1131